RRx 001

Drug Profile

RRx 001

Alternative Names: ABDNAZ; RRx-001

Latest Information Update: 23 Dec 2016

Price : $50

At a glance

  • Originator RadioRx
  • Developer EpicentRx
  • Class Antineoplastics; Azetidines; Nitro compounds; Small molecules
  • Mechanism of Action Free radical stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cholangiocarcinoma; Colorectal cancer; Neuroendocrine tumours; Non-small cell lung cancer; Small cell lung cancer
  • Phase I Lymphoma; Solid tumours

Most Recent Events

  • 12 Nov 2016 Preclinical data from studies in mice model were presented at the 89th Annual Scientific Sessions of the American Heart Association (AHA-2016)
  • 15 Aug 2016 EpicentRx plans the phase I G-FORCE-1 trial for Glioblastoma and Oligodendroglioma (Adjunctive treatment, Newly diagnosed, Late-stage disease) in USA (IV) (NCT02871843)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Lymphoma(Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top